- Service Name
TriLink BioTechnologies
- Industry
Biotechnology, Nucleic Acids, mRNA Synthesis, Custom Chemistry
- Main Value Proposition
TriLink provides innovative nucleic acid tools and services that accelerate the development of transformative nucleic acid therapies, ensuring high-quality and scalable solutions for researchers and developers.
- Description
TriLink BioTechnologies specializes in the synthesis of highly modified nucleic acid constructs, including custom mRNA, for research, diagnostic, and therapeutic applications. Their innovative technologies and services support the development of nucleic acid therapies from research to clinical applications.
- Key Features
CleanCap® technology for enhanced mRNA stability and expression; Custom synthesis of modified nucleotides and oligonucleotides; Comprehensive CDMO services for mRNA manufacturing; Extensive analytical support for quality assurance
- Use Cases
Research and development of mRNA-based therapeutics; Clinical trials for vaccine development; Custom synthesis of nucleotides for diagnostic applications; Support for commercial manufacturing of mRNA products
- Competitive advantages
Proven expertise with over 25 years in nucleic acid product development and manufacturing; GMP-grade manufacturing capabilities that meet rigorous industry standards; Strong partnerships with leading global pharmaceutical companies for enhanced credibility and reach
- Strengths
TriLink's strengths lie in its innovative technologies, extensive experience in the field, and commitment to quality and scalability in mRNA production.
- Positioning
TriLink positions itself as a leading innovator in the mRNA space, providing comprehensive solutions that bridge the gap between research and clinical application.
- Audience
The primary target users include pharmaceutical companies, biotech firms, academic researchers, and institutions involved in nucleic acid research and development.
- Brand Positioning
TriLink is recognized as a trusted partner in the nucleic acid industry, known for its high-quality products and commitment to advancing mRNA technology.
- CTA
Contact us about your project
- Differentiation
TriLink's unique CleanCap® technology revolutionizes mRNA capping strategies, offering superior efficiency and effectiveness in mRNA synthesis compared to traditional methods.
- Tagline
Unleashing the power of mRNA
- Tags
mRNA
Nucleotides
Custom Synthesis
Biotechnology
- Tone of Voice
Professional, Innovative, Supportive
- Founded
1996-01-01
- Founders
Richard Hogrefe
Terry Beck